Brooklyn ImmunoTherapeutics (BTX) Stock Pulls Back Sharply: A Good Buy Now?

Over the past couple of weeks, Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX) has been in focus among many investors due to a range of key developments. Earlier this week, the company announced that it had been published in Breast Cancer Research.

Brooklyn ImmunoTherapeutics (BTX) Stock Pulls Back Sharply: A Good Buy Now?

In the paper, the company demonstrated how multiplex immunofluorescence (mIF) may be deployed in relation to the treatment of breast cancer. The publication is entitled “Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.”

Related:  Ocugen (OCGN) Soars Suddenly Last Week: Is The Best News To Come?

The study revealed the way in which mIF may be deployed to get a comprehensive idea about the immunological activity of IRX-2. The Chief Executive Officer of the company Howard Federoff spoke about the study and stated that Brooklyn ImmunoTherapeutics is excited that IRX-2 has been validated by way of unbiased technology. It is a significant development for the company and it now remains to be seen if it has any effect on its stock.

Anthony Gonzales

Biotech, Tech, and Crypto reporter Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.